Supporting the Head and Neck Cancer Community, Yesterday, Today and Tomorrow
27 JUL 2022
For the more than 740,000 people diagnosed with head and neck cancers globally each year, the disease can be extremely difficult to deal with, underscoring the importance of research into new treatments.
Head and neck cancers occur in the cells that line tissues or organs in the head and neck region, such as the throat, voice box, and nasal cavity. Globally, researchers estimate over 740,000 new cases of head and neck cancer are diagnosed each year, including 140,000 new cases each year in Europe.1 Treatments for head and neck cancers depend on the location and stage and may include surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or a combination of treatments.2
For nearly two decades, Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the US and Canada, has been focused on providing and developing medicines that can make a difference in the lives of those faced with some of the most challenging cancers, such as head and neck cancers. Our Head of Development Unit Oncology, Victoria Zazulina, discusses the company’s history and commitment to supporting those with head and neck cancers and our efforts to improve outcomes for this disease.
HCPs interested in learning more about our research in head and neck cancers, visit https://www.emdseronooncology.com/en/our-science/oncogenic-signaling/IAP/
1 ESMO. Head & Neck Cancers: Epidemiology, risk factors and pathogensis of squamous cell tumours. 2017. p. 1–6. http://oncologypro.esmo.org/content/download/113133/1971849/file/2017-ESMO-Essentials-for-Clinicians-Head-Neck-Cancers-Chapter-1.pdf (accessed August 2019)
2 National Institutes of Health. National Cancer Institute. Head and neck cancers. Reviewed May 25, 2021. Available at: https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet#how-common-are-head-and-neck-cancers. Accessed March 31, 2022